Newly developed retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is sparking considerable excitement within the medical community. Initial clinical studies have shown impressive losses in physical weight and advancements in health markers for people with excess weight . Experts believe this unique approach could repre